China CanSinoBIO's vaccine 57.5% effective against COVID in Phase III trial-study | Reuters

Retrieved on: 2021-12-24 16:00:43

Tags for this article:

Click the tags to see associated articles and topics

China CanSinoBIO's vaccine 57.5% effective against COVID in Phase III trial-study | Reuters. View article details on hiswai:

Excerpt

CanSino Biologics Inc's vaccine was 57.5% effective against symptomatic COVID-19 and 91.7% against severe disease four weeks or longer after one ...

Article found on: www.reuters.com